-
Product Insights
Knee Reconstruction – Engage Surgical – ENGAGE PARTIAL KNEE SYSTEM
GlobalData, the industry analysis specialist, has released its latest report: Knee Reconstruction - Engage Surgical - ENGAGE PARTIAL KNEE SYSTEM. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted...
-
Product Insights
Introducer Sheaths – Abbott Laboratories – ENGAGE
GlobalData, the industry analysis specialist, has released its latest report: Introducer Sheaths - Abbott Laboratories - ENGAGE. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the discounting...
-
Product Insights
Introducer Sheaths – Abbott Laboratories – ENGAGE TR
GlobalData, the industry analysis specialist, has released its latest report: Introducer Sheaths - Abbott Laboratories - ENGAGE TR. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the...
-
Thematic Analysis
New![]()
Insurtech – Thematic Intelligence
Insurtech Thematic Report Overview Insurtechs can create innovative solutions for content generation using generative AI, risk modeling, and customer engagement. For instance, they can use generative AI to generate personalized insurance policies based on customer data, enhancing customer experiences and increasing policy uptake. Additionally, generative AI can be utilized to create interactive chatbots or virtual assistants that provide real-time support and streamline claims processing. Thus, by leveraging generative AI's ability to generate new content, insurtechs can also improve marketing efforts,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JANX-007 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JANX-007 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:JANX-007 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-217 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-217 in Refractory Multiple Myeloma Drug Details:HPN-217 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPN-217 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HPN-217 in Relapsed Multiple Myeloma Drug Details:HPN-217 is under development for the treatment of relapsed and...
-
Case Studies
NewScrub Daddy – Success Case Study
Scrub Daddy - Success Case Study is part of GlobalData's Success and Failures case study series, which explores the reasons underpinning success or failure, and key learnings. Scrub Daddy is a premium scouring product that has attracted a huge online following and used TV show "Shark's Den" as a part of the springboard to success. Scrub Daddy has managed to capture the attention of consumers in an otherwise low-engagement category by smart use of social media. The product itself leans...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Obexelimab in Acquired (Autoimmune) Hemolytic Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Obexelimab in Acquired (Autoimmune) Hemolytic Anemia Drug Details: Obexelimab (XmAb-5871) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMX-818 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AMX-818 in Solid Tumor Drug Details: AMX-818 is under development for the treatment of HER2 low...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) Drug Details: Obexelimab (XmAb-5871) is under development for the...
-
Analyst Opinions
NewTrust and Transparency – Consumer TrendSights Analysis, 2023
Trust and Transparency - Consumer TrendSights Report Overview The level of engagement with the trust & transparency trend is determined by factors such as time and cost pressures, social media use, and political influence. While trust in brand information is high overall, a significant number of consumers remain skeptical and even confused about what to believe. Modern consumers expect a variety of information to be made available by brands, particularly around health, and third-party validation remains important. The trust and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elranatamab in Multiple Myeloma (Kahler Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elranatamab in Multiple Myeloma (Kahler Disease) Drug Details: Elranatamab-bcmm (Elrexfio) is a bispecific, humanized immunoglobulin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DF-8001 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DF-8001 in Solid Tumor Drug Details: DF-8001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANJ-564 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ANJ-564 in Solid TumorDrug Details:ANJ-564 is under development for the treatment of myelodysplastic syndrome, and solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Linvoseltamab in Multiple Myeloma (Kahler Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Linvoseltamab in Multiple Myeloma (Kahler Disease) Drug Details: Linvoseltamab (REGN-5458) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IGM-2644 in Relapsed Multiple Myeloma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IGM-2644 in Relapsed Multiple Myeloma Drug Details: IGM-2644 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IGM-2644 in Refractory Multiple Myeloma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IGM-2644 in Refractory Multiple Myeloma Drug Details: IGM-2644 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TI-1007 in B-Cell Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TI-1007 in B-Cell Non-Hodgkin LymphomaDrug Details:TI-1007 is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TJL-14B in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TJL-14B in Solid Tumor Drug Details: TJL-14B is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.